Offringa R - Search Results

1

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.

Menon AG, Kuppen PJ, van der Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ. Menon AG, et al. Among authors: offringa r. Cancer Gene Ther. 2003 Jul;10(7):509-17. doi: 10.1038/sj.cgt.7700600. Cancer Gene Ther. 2003. PMID: 12833131

2

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb AJ, Melief CJ. Kast WM, et al. Among authors: offringa r. Cell. 1989 Nov 17;59(4):603-14. doi: 10.1016/0092-8674(89)90006-8. Cell. 1989. PMID: 2555063

3

Immunosurveillance of virus-induced tumors.

Melief CJ, Vasmel WL, Offringa R, Sijts EJ, Matthews EA, Peters PJ, Meloen RH, van der Eb AJ, Kast WM. Melief CJ, et al. Among authors: offringa r. Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:597-603. doi: 10.1101/sqb.1989.054.01.071. Cold Spring Harb Symp Quant Biol. 1989. PMID: 2700948 Review. No abstract available.

4

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. J Immunol. 1995 Apr 1;154(7):3396-405. J Immunol. 1995. PMID: 7534797

5

Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.

Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Behring Inst Mitt. 1994 Jul;(94):72-86. Behring Inst Mitt. 1994. PMID: 7998917 Review.

6

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape.

Toes RE, Feltkamp MC, Ressing ME, Vierboom MP, Blom RJ, Brandt RM, Hartman M, Offringa R, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Biochem Soc Trans. 1995 Aug;23(3):692-6. doi: 10.1042/bst0230692. Biochem Soc Trans. 1995. PMID: 8566445 Review. No abstract available.

7

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Toes RE, et al. Among authors: offringa r. J Immunol. 1996 May 15;156(10):3911-8. J Immunol. 1996. PMID: 8621930

8

Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts.

Toes RE, Kast WM, Blom RJ, Bakker SC, Offringa R, Melief CJ. Toes RE, et al. Among authors: offringa r. Int J Cancer. 1996 May 29;66(5):686-91. doi: 10.1002/(SICI)1097-0215(19960529)66:5<686::AID-IJC17>3.0.CO;2-2. Int J Cancer. 1996. PMID: 8647633

9

Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.

Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Cancer Res. 1996 Aug 15;56(16):3782-7. Cancer Res. 1996. PMID: 8706024

10

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7855-60. doi: 10.1073/pnas.93.15.7855. Proc Natl Acad Sci U S A. 1996. PMID: 8755566 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

267 results

Search Page

Filters